---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-059522"
form_type: "8-K"
ticker: null
cik: "0001661460"
company_name: "Poseida Therapeutics, Inc."
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:56:54.179866+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Poseida Q1 rev $28.1M, net loss $24.3M; Astellas $50M upfront collab, new CMO

## Summary
- Revenue $28.1M vs $10.3M YoY; net loss $24.3M vs $38.8M; cash $198.6M, runway into H2 2025.
- Astellas research collaboration: $50M upfront, up to $550M milestones, low double-digit royalties for solid tumor CAR-T.
- Roche partnership: $30M milestone in Q1, $15M expected May 2024; total $95M in 2024 milestones/upfront.
- P-BCMA-ALLO1 data: 60% overall response rate in RRMM patients after prior BCMA-directed therapy.
- Appointed Syed Rizvi, M.D., as Chief Medical Officer in April 2024.

## SEC filing metadata
- accession: 0000950170-24-059522
- form_type: 8-K
- cik: 0001661460
- company_name: Poseida Therapeutics, Inc.
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/0000950170-24-059522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/pstx-20240514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-059522
- JSON: https://secwatch.observer/filing/0000950170-24-059522.json
- Plain text: https://secwatch.observer/filing/0000950170-24-059522.txt

## Key facts
- Earnings Releases
  Poseida Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 14, 2024, Poseida Therapeutics, Inc. (the “Company”) issued a press release announcing its updates and financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1661460/000095017024059522/0000950170-24-059522-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.